Skip to main content

Table 3 Descriptive statistics of each MDR microorganism regarding antibiotic combinations and affected systems

From: Incidence of emerging multidrug-resistant organisms and its impact on the outcome in the pediatric intensive care

Parameter MDR Acinetobacter
(n=14)
MDR Klebsiella
(n=12)
MDR Pseudomonas
(n=2)
Antibiotic used
 Piperacillin Tazobactam + Colistimethate sodium 5 (35.7%) 8 (66.6%) 2 (100%)
 Imipenem+ Colistimethate sodium 6 (42.8%) 4 (33.3%) -
 Ceftazidime-Clindamycin – Amikacin - 1 (8.3%) -
 Colistimethate sodium and Ciprofloxacin 1 (7.1%) - -
 Piperacillin Amikacin 1 (7.1%) - -
 Meropenem+ Amikacin 1 (7.1%) - -
Samples
 Sputum 10 (71.4%) 5 (41.6%) -
 Blood 2 (14.3%) 4 (33.3%) 1 (50%)
 Urine 2 (14.3%) 3 (25%) 1 (50%)